CYAD.BR
Price:
$0.237
Market Cap:
$9.82M
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's precl...[Read more]
Industry
Biotechnology
IPO Date
2013-07-04
Stock Exchange
EURONEXT
Ticker
CYAD.BR
According to Celyad Oncology SA’s latest financial reports and current stock price. The company's current PE Ratio is -0.17. This represents a change of -77.42% compared to the average of -0.75 of the last 4 quarters.
The mean historical PE Ratio of Celyad Oncology SA over the last ten years is -5.92. The current -0.17 PE Ratio has changed 187.36% with respect to the historical average. Over the past ten years (40 quarters), CYAD.BR's PE Ratio was at its highest in in the December 2020 quarter at 4.78. The PE Ratio was at its lowest in in the March 2012 quarter at -48.98.
Average
-5.92
Median
-5.18
Minimum
-14.20
Maximum
-0.28
Discovering the peaks and valleys of Celyad Oncology SA PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 325.17%
Maximum Annual PE Ratio = -0.28
Minimum Annual Increase = -86.50%
Minimum Annual PE Ratio = -14.20
Year | PE Ratio | Change |
---|---|---|
2023 | -1.19 | 325.17% |
2022 | -0.28 | -86.50% |
2021 | -2.07 | -60.77% |
2020 | -5.27 | 24.31% |
2019 | -4.24 | -16.63% |
2018 | -5.09 | -13.51% |
2017 | -5.88 | -16.26% |
2016 | -7.03 | -50.51% |
2015 | -14.20 | 2.09% |
2014 | -13.91 | 63.96% |
The current PE Ratio of Celyad Oncology SA (CYAD.BR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.18
5-year avg
-2.61
10-year avg
-5.92
Celyad Oncology SA’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Celyad Oncology SA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Celyad Oncology SA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Celyad Oncology SA's PE Ratio?
How is the PE Ratio calculated for Celyad Oncology SA (CYAD.BR)?
What is the highest PE Ratio for Celyad Oncology SA (CYAD.BR)?
What is the 3-year average PE Ratio for Celyad Oncology SA (CYAD.BR)?
What is the 5-year average PE Ratio for Celyad Oncology SA (CYAD.BR)?
How does the current PE Ratio for Celyad Oncology SA (CYAD.BR) compare to its historical average?